Our AI-native platform creates mechanisms that natural evolution never produced and accelerates the path from concept to clinic. We focus on immune-mediated diseases with high unmet need, where current biologics and small molecules fail too many patients.
Immune diseases continue to rise. Many patients don’t respond to today’s therapies or lose response over time. Evozyne designs and builds proteins with precision, durability, and selectivity that overcome these limitations.
EvoGen, our AI-native engine, learns how protein sequences drive function. It designs new proteins optimized for potency, stability, specificity, and immunogenicity.
EvoLab, our high-throughput experimental facility, synthesizes and evaluates thousands of candidates each design cycle generating vast troves of novel, proprietary data.
We move proteins engineered for therapeutic use into our immunology pipeline, including IgG proteases, next-generation cytokines, and respiratory disease candidates.
Evozyne is one of the few AI-native biotechs creating de novo therapeutic proteins and advancing them toward clinical evaluation. As the system learns, the pipeline expands, creating a scalable path to new immune therapies.
Peer-reviewed publications demonstrate platform performance, including:
